JBIO
Jade Biosciences, Inc.
1W: +1.2%
1M: +0.5%
3M: -17.3%
YTD: -1.5%
$13.95
+0.69 (+5.20%)
After Hours: $12.03 (-1.92, -13.80%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$28.7M
Congress—
ETF Holdings—
Key Statistics
Market Cap$455.1M
52W Range6.565-100.1
Volume369,611
Avg Volume326,457
Beta1.03
Dividend$2.40
Analyst Ratings
Company Info
CEOTom Frohlich
Employees50
SectorHealthcare
IndustryBiotechnology
IPO Date2025-04-29
Websitejadebiosciences.com
221 Crescent Street Building 23
Waltham, MA 02453
US
Waltham, MA 02453
US
1 916-322-1700
About Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Latest News
Jade Biosciences (NASDAQ:JBIO) Shares Gap Up After Analyst Upgrade
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Jade Biosciences, Inc. reports Q4 results
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Dahms Bradford D. | A-Award | 37,813 | — | 2026-02-12 |
| Dahms Bradford D. | A-Award | 226,875 | $14.81 | 2026-02-12 |
| Balta Elizabeth | A-Award | 28,125 | — | 2026-02-12 |
| Balta Elizabeth | A-Award | 168,750 | $14.81 | 2026-02-12 |
| Frohlich Tom | A-Award | 78,750 | — | 2026-02-12 |